Skip to content

EU · EudraLex Vol.4

EU GMP Part I, Chapter 3

Premises and Equipment

Status of the document: Revisiona.

Table of contents

  1. PrinciplePrinciple
  2. 3.1Premises should be situated in an environment which, when considered together with measures to protect the manufacture, presents minimal ri…
  3. 3.2Premises should be carefully maintained, ensuring that repair and maintenance operations do not present any hazard to the quality of produc…
  4. 3.3Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, e…
  5. 3.4Premises should be designed and equipped so as to afford maximum protection against the entry of insects or other animals.
  6. 3.5Steps should be taken in order to prevent the entry of unauthorised people. Production, storage and quality control areas should not be use…
  7. 3.6Cross-contamination should be prevented for all products by appropriate design and operation of manufacturing facilities. The measures to p…
  8. 3.7Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresp…
  9. 3.8The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as…
  10. 3.9Where starting and primary packaging materials, intermediate or bulk products are exposed to the environment, interior surfaces (walls, flo…
  11. 3.10Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses which are di…
  12. 3.11Drains should be of adequate size, and have trapped gullies. Open channels should be avoided where possible, but if necessary, they should…
  13. 3.12Production areas should be effectively ventilated, with air control facilities (including temperature and, where necessary, humidity and fi…
  14. 3.13Weighing of starting materials usually should be carried out in a separate weighing room designed for such use.
  15. 3.14In cases where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of dry products), specific pr…
  16. 3.15Premises for the packaging of medicinal products should be specifically designed and laid out so as to avoid mix-ups or cross-contamination.
  17. 3.16Production areas should be well lit, particularly where visual on-line controls are carried out.
  18. 3.17In-process controls may be carried out within the production area provided they do not carry any risk to production.
  19. 3.18Storage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products: starting and p…
  20. 3.19Storage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean and dry and maintained w…
  21. 3.20Receiving and dispatch bays should protect materials and products from the weather. Reception areas should be designed and equipped to allo…
  22. 3.21Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authoris…
  23. 3.22There should normally be a separate sampling area for starting materials. If sampling is performed in the storage area, it should be conduc…
  24. 3.23Segregated areas should be provided for the storage of rejected, recalled or returned materials or products.
  25. 3.24Highly active materials or products should be stored in safe and secure areas.
  26. 3.25Printed packaging materials are considered critical to the conformity of the medicinal product and special attention should be paid to the…
  27. 3.26Normally, Quality Control laboratories should be separated from production areas. This is particularly important for laboratories for the c…
  28. 3.27Control laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix-ups…
  29. 3.28Separate rooms may be necessary to protect sensitive instruments from vibration, electrical interference, humidity, etc.
  30. 3.29Special requirements are needed in laboratories handling particular substances, such as biological or radioactive samples.
  31. 3.30Rest and refreshment rooms should be separate from other areas.
  32. 3.31Facilities for changing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. To…
  33. 3.32Maintenance workshops should as far as possible be separated from production areas. Whenever parts and tools are stored in the production a…
  34. 3.33Animal houses should be well isolated from other areas, with separate entrance (animal access) and air handling facilities.
  35. 3.34Manufacturing equipment should be designed, located and maintained to suit its intended purpose.
  36. 3.35Repair and maintenance operations should not present any hazard to the quality of the products.
  37. 3.36Manufacturing equipment should be designed so that it can be easily and thoroughly cleaned. It should be cleaned according to detailed and…
  38. 3.37Washing and cleaning equipment should be chosen and used in order not to be a source of contamination.
  39. 3.38Equipment should be installed in such a way as to prevent any risk of error or of contamination.
  40. 3.39Production equipment should not present any hazard to products. Parts of production equipment that come into contact with the product must…
  41. 3.40Balances and measuring equipment of an appropriate range and precision should be available for production and control operations.
  42. 3.41Measuring, weighing, recording and control equipment should be calibrated and checked at defined intervals by appropriate methods. Adequate…
  43. 3.42Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.
  44. 3.43Distilled, deionised and, where appropriate, other water pipes should be sanitised according to written procedures that detail the action l…
  45. 3.44Defective equipment should, if possible, be removed from production and quality control areas, or at least be clearly labelled as defective.
Cover page and contents (original)

Ref. Ares(2015)283695 - 23/01/2015

PT CHAPTER 5 PRODUCTION EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health systems and products Medicinal products – quality, safety and efficacy

Brussels, 13 August 2014 EudraLex

The Rules Governing Medicinal Products in the European Union Volume 4

EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Part 1 Chapter 3: Premises and Equipment

Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.

Status of the document: Revisiona.

Reasons for changes: The only change is to section 6 as part of the improved guidance on prevention of cross-contamination involving also Chapter 5.

Deadline for coming into operation: 1 March 2015. However, the toxicological evaluation mentioned in section 6 is to be carried out:

• from 1 June 2015 onwards for any medicinal product newly introduced into shared manufacturing facilities;

• before 1 December 2015 for medicinal products already produced in a shared manufacturing facility producing only medicinal products for human use or both producing medicinal products for human use and veterinary medicinal products on 31 May 2015;

• before 1 June 2016 for veterinary medicinal products already produced in a shared manufacturing facility producing only veterinary medicinal products on 31 May 2015.

a In January 2015 the deadline for coming into operation was adapted with regard to the toxicological evaluation to align with the coming effect of the EMA guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11

ER 3 PREMISES AND EQUIPMENT

Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.